MedKoo Cat#: 462040 | Name: Terodiline hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Terodiline hydrochloride is a is a non-selective calcium channel antagonist with anticholinergic and vasodilatory activity.

Chemical Structure

Terodiline hydrochloride
Terodiline hydrochloride
CAS#7082-21-5

Theoretical Analysis

MedKoo Cat#: 462040

Name: Terodiline hydrochloride

CAS#: 7082-21-5

Chemical Formula: C20H28ClN

Exact Mass: 317.1910

Molecular Weight: 317.90

Elemental Analysis: C, 75.56; H, 8.88; Cl, 11.15; N, 4.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Terodiline hydrochloride; Mictrol; Micturol; Terodiline HCl; TD-758
IUPAC/Chemical Name
Benzenepropanamine, N-(1,1-dimethylethyl)-alpha-methyl-gamma-phenyl-, hydrochloride
InChi Key
RNGHAJVBYQPLAZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H27N.ClH/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5-14,16,19,21H,15H2,1-4H3;1H
SMILES Code
CC(NC(C)(C)C)CC(C1=CC=CC=C1)C2=CC=CC=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
Safety Data Sheet (SDS)

Preparing Stock Solutions

The following data is based on the product molecular weight 317.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. S. H. Thomas, P. D. Higham, K. Hartigan-Go, F. Kamali, P. Wood, R. W. Campbell, G. A. Ford Br Heart J. 1995 Jul; 74(1): 53–56. doi: 10.1136/hrt.74.1.53 PMCID: PMC483946 2: Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials Stephen E Jones, Lesya M Shuba, Pavel Zhabyeyev, John R McCullough, Terence F McDonald Br J Pharmacol. 2000 Sep; 131(2): 245–254. doi: 10.1038/sj.bjp.0703595 PMCID: PMC1572333 3: Terodiline with bladder retraining for treating detrusor instability in elderly people. P A Wiseman, J Malone-Lee, G S Rai BMJ. 1991 Apr 27; 302(6783): 994–996. doi: 10.1136/bmj.302.6783.994 PMCID: PMC1669297 4: Block and modified gating of cardiac calcium channel currents by terodiline Toshitsugu Ogura, Stephen Jones, Lesya M Shuba, John R McCullough, Terence F McDonald Br J Pharmacol. 1999 Aug; 127(8): 1837–1845. doi: 10.1038/sj.bjp.0702713 PMCID: PMC1566165 5: CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system Gary A Ford, Susan M Wood, Ann K Daly Br J Clin Pharmacol. 2000 Jul; 50(1): 77–80. doi: 10.1046/j.1365-2125.2000.00230.x PMCID: PMC2014965 6: Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline Stephen E Jones, Toshitsugu Ogura, Lesya M Shuba, Terence F McDonald Br J Pharmacol. 1998 Nov; 125(6): 1138–1143. doi: 10.1038/sj.bjp.0702173 PMCID: PMC1565686 7: A calcium blocking and anticholinergic agent (terodiline) in the treatment of detrusor hyperreflexia: a placebo-controlled, cross-over trial. T Petersen, J Jakobsen J Neurol Neurosurg Psychiatry. 1987 Oct; 50(10): 1331–1336. doi: 10.1136/jnnp.50.10.1331 PMCID: PMC1032460 8: Terodiline for treating detrusor instability in elderly people. G Boyd BMJ. 1991 Jul 13; 303(6794): 124. doi: 10.1136/bmj.303.6794.124-c PMCID: PMC1670621 9: Diagnosis and management of female urinary incontinence in general practice. J V Jolleys J R Coll Gen Pract. 1989 Jul; 39(324): 277–279. PMCID: PMC1711911 10: Terodiline for treating detrusor instability in elderly people. S W Davies, S J Brecker, R N Stevenson BMJ. 1991 May 25; 302(6787): 1276. doi: 10.1136/bmj.302.6787.1276 PMCID: PMC1669941